vildagliptin (Galvus)

Return to the home page of the Diabetes Monitor

Galvus® (vildagliptin) is a drug in a new class of oral diabetes medications, called DPP-4 inhibitors. It is available in Europe, but not in the United States.

vildagliptin

Brand name in US: Galvus®
Class: DPP-4 inhibitor
For: Type 2 diabetes
Route of Administration: oral
Action: inhibits DPP-4 (dipeptidyl peptidase-4), allowing potentiation of the secretion of insulin by beta cells.
Manufacturer: Novartis
Status: Approved in Europe February 2008. FDA asked for additional safety data, November 2006
Source: Press release from manufacturer, Novartis: Galvus®, a new treatment for patients with type 2 diabetes, receives European approval for label update paving the way for EU launches
Other drugs in the same class: Januvia (sitagliptin) (approved in US and Europe); Onglyza® (saxagliptin) (approved in US; undergoing EU review as of summer 2009).

Also see

VildagliptinAt Wikipedia.
Novartis Announces Three-month Extension Of US Regulatory Review For Galvus® To Assess Recently Available Clinical Data (15 Nov 2006) At Medical News Today.

Search the DiabetesMonitor for more information about

Advertisements

[Top]

Webpage new at the DiabetesMonitor 04Aug2009

Send us an e-mail at info@diabetesmonitor.com